1 / 39

Stephan Moll, MD University of North Carolina Chapel Hill, N.C. Dept. of Medicine, Heme-Onc smoll@med.unc Tel: 919-966-3

Venous Thromboembolism. Stephan Moll, MD University of North Carolina Chapel Hill, N.C. Dept. of Medicine, Heme-Onc smoll@med.unc.edu Tel: 919-966-3311 Richmond 9/29/2006. A. Diagnosis. Clinical assessment. D-dimer. B. Treatment. LMWH, Fondaparinux, unfract. Heparin.

salena
Télécharger la présentation

Stephan Moll, MD University of North Carolina Chapel Hill, N.C. Dept. of Medicine, Heme-Onc smoll@med.unc Tel: 919-966-3

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Venous Thromboembolism Stephan Moll, MD University of North Carolina Chapel Hill, N.C. Dept. of Medicine, Heme-Onc smoll@med.unc.edu Tel: 919-966-3311 Richmond 9/29/2006

  2. A. Diagnosis Clinical assessment D-dimer B. Treatment LMWH, Fondaparinux, unfract. Heparin Outpatient versus inpatient Length of warfarin postthrombotic syndrome C. Other Education resources Overview

  3. Case - History • HPI • 28 yr old woman with • left calf pain x 1 week • noticeable left ankle + thigh swelling • started without trigger • PMH • appendectomy age 16 • obesity (BMI 32.0) • Family Hx • Large family • Maternal grandmother: “clot in her leg at 63” • Meds • Yasmin®

  4. L > R by 4 cm L > R by 2.5 cm Case – Physical Examination

  5. Pre-test Probability - DVT • Clinical characteristics (Well’s criteria): • Active cancer • Paralysis or plaster immobilization • Bedridden ≥ 3 d; major surgery in 3 mo • Entire leg swollen • Calf swelling > 3cm • Pitting edema in affected leg • Collateral non-varicose superficial veins • Localized tenderness along deep veins • Previous DVT • Alternative dx more likely 1 1 1 1 1 1 1 1 1 -2 • score < 2: DVT unlikely • score ≥ 2: DVT likely • OCP, pregnancy, HRT [Wells PS. NEJM 2003;349:1227-35]

  6. fibrin D D D D D D D-Dimer fibrinolytic system

  7. D-dimer pos neg no test, no anticoag. imaging test Clinical Suspicion for DVT unlikely likely [Wells PS. NEJM 2003;349:1227-35]

  8. Clinical characteristics (Well’s criteria): • Active cancer • Paralysis or plaster immobilization • Bedridden ≥ 3 d; major surgery in 3 mo • Entire leg swollen • Calf swelling > 3cm • Pitting edema in affected leg • Collateral non-varicose superficial veins • Localized tenderness along deep veins • Previous DVT • Alternative dx more likely 1 1 1 1 1 1 1 1 1 -2 Case – Physical Examination L > R by 2.5 cm • score < 2: DVT unlikely • score ≥ 2: DVT likely

  9. D-dimer pos neg no test, no anticoag. imaging test Clinical Suspicion for DVT unlikely likely [Wells PS. NEJM 2003;349:1227-35]

  10. Clinical characteristics (Well’s criteria): • Active cancer • Paralysis or plaster immobilization • Bedridden ≥ 3 d; major surgery in 3 mo • Entire leg swollen • Calf swelling > 3cm • Pitting edema in affected leg • Collateral non-varicose superficial veins • Localized tenderness along deep veins • Previous DVT • Alternative dx more likely 1 1 1 1 1 1 1 1 1 -2 Case – Physical Examination • score < 2: DVT unlikely • score ≥ 2: DVT likely

  11. D-dimer pos neg no test, no anticoag. imaging test Clinical Suspicion for DVT unlikely likely [Wells PS. NEJM 2003;349:1227-35]

  12. DVT Diagnosis • Doppler ultrasound • CT venogram • MR venogram • Contrast venography

  13. D-Dimer Caveats • Know which test your lab uses • Neg. D-Dimer does not r/o distal DVT

  14. Pre-test Probability - PE • Pre-test probability for PE: • Active cancer • Bedridden ≥ 3d or major surgery past 4 wks • Previous DVT/PE • Hemoptysis • Heart rate > 100/min • PE is most likely dx • Clinical signs + symptoms c/w DVT 1 1.5 1.5 1 1.5 3 3 • score ≤ 4: PE unlikely • score 4-6: moderate probability • > 6 high probability [Kearon, C. Ann Intern Med 2006;144:812-821] [Wells PS. Thromb Haemost. 2000;83:416-20]

  15. D-dimer pos neg no test, no anticoag. imaging test Clinical Suspicion for PE low moderate or high [Kearon, C. Ann Intern Med 2006;144:812-821] [Wells PS. Thromb Haemost. 2000;83:416-20]

  16. PE Diagnosis • Spiral (helical; PE-protocol) CT • VQ scan

  17. Treatment – Thrombolytics • Does thrombolytic Rx ↓ development of PTS? • Not appropriately studied. ACCP guidelines for DVT: • Recommend against routine use [1A] • Confined to selected patients (limb salvage) [2C] [ACCP guidelines. Büller H et al. Chest 2004;126:401S-428S]

  18. Thrombolytics in DVT My approach/indications: • Massive DVT (phlegmasia coerulea dolens) • Young patient with extensive DVT • Cancer patient – quality of life, short-term • Individual discussion • Catheter-directed, tPA 0.5 mg/h (1-2 ports) for 24 hr or longer

  19. Thrombolytics in PE • Give in life-threatening PE • Consider in “submassive” PE (pulm. HTN or right ventricular dysfunction [NEJM 2002;347:1143-50] [NEJM 2002;347:1131-32]

  20. Treatment – Distal DVT • Proximal = popliteal vein and above • 1st DVT with transient risk factor: Symptomatic calf vein DVT: Rx same as prox DVT • Spontaneous distal DVT: no comments [ACCP guidelines. Büller H et al. Chest 2004;126:401S-428S; page 410S]

  21. Treatment – 1st Few Days • LMWH • Fondaparinux • Unfractionated heparin [Büller HR. NEJM 2003;349:1695-702] [Büller HR. Ann Intern Med 2004;140:867-873] • Overlap for at least 5 days

  22. Treatment – Outpatient? Outpatient Rx: • Effective • Safe • Feasable • Cost saving ACCP on Acute DVT and PE: • LMWH qd or q 12 hr preferred over UFH (DVT/PE) • Outpatient if possible (DVT) [Büller H et al. Chest 2004;126:401S-428S] Admission: • significant DVT • “free-floating thrombus” • significant PE

  23. Treatment – Outpatient? • Think twice! • Can patient afford cost of LMWH? • S.c. injection teaching • Access to INR-determination (anticoagulation clinic) • Warfarin dosing (nomogram) • Warfarin teaching • Elastic bandages/stockings – prescription Outpatient Rx • LMWH q 12 hr or q d • Fondaparinux q d • S.c. heparin, fixed-dose [NEJM 2006]

  24. = TED Postthrombotic Syndrome Compression stockings • Grade 2, graduated (35 mm Hg at ankle, 25 at mid-calf, 18 at thigh) • individually fitted • below knee / above knee • as long as there is leg swelling

  25. Postthrombotic Syndrome

  26. Case – Thrombophilia w/u • Thrombophilia w/u: • FVLeiden • II 20210 mutation • ATIII activity • Protein C activity • Protein S test • Homocysteine • Anticardiolipin antibodies • Lupus anticoagulant • Anti-β2-glycoportein I antibodies

  27. DVT Recurrence Rate • Low • Transient risk factor • Moderate • No abnormality detected • hetero factor V Leiden • hetero II 20210 Spontaneous VTE • Higher • APLA • AT III • hetero FVLeiden plus II 20210 • homo factor V Leiden?

  28. DVT Recurrence Rate [NEJM 2004;350:2558-63]

  29. DVT Recurrence Rate • D-dimer pos • Residual clot • Elevated factor VIII • Elevated factor IX • Elevated factor XI • Men > women D-dimer (on anticoagulants) VIII [Thromb Haemost 2002;88:162-3] [NEJM 2000;343:457-62] [Blood 2003;102:abstract 1133] [NEJM 2004;350:2558-63] [Br J Haematol 2004;124:504-10] D-dimer (off anticoagulants) [Thromb Haemost 2002;87:7-12] [Blood 2004;103:3773-6] [JTH 2006;4:1208-14] Residual clot IX [Blood 2004;103:3773-6] XI [Blood 2004;103:3773-6]

  30. Obtain: D-dimer Doppler legs Lowest risk: woman; DVT; neg. D-dimer; no residual clot; was on OCP Stop warfarin INR 2.0- 3.0 • Stable INRs? • Bleeding • Lifestyle changes? • Patient preference Highest risk: man, PE; pos. D-dimer; + residual clot Length of warfarin Rx My own approach Acute DVT/PE 6 mo

  31. Low-dose warfarin? • Full-intensity warfarin (INR 2-3) is more effective than low-intensity (INR 1.5-2.0) • Low-intensity is also effective • Bleeding with full-intensity warfarin is similar to low-intensity • When choosing long-term warfarin, choose full-intensity. [PREVENT trial: NEJM 2003;348:1425-34] [ELATE trial: NEJM 2003;349:631-639]

  32. Case – @ 6 months • Significant chronic left leg swelling + pain • D-dimer negative • Doppler Ultrasound: - “Leg: no residual clot”- “Suggestion of obstruction prox. to inguinal ligament”. • You think she may have……? May Thurner syndrome • You order…..? Pelvic CT or MR venogram

  33. May Thurner Syndrome Stenting

  34. Postthrombotic Syndrome • www.biocompression.com • www.lympha-press.com

  35. Thrombosis risk Birth Control Options • Estrogen combination pill • 3rd generation • 2nd generation ??? Yasmin® Ortho Evra® • Progestin-only • Depot Provera® • Minipill • Mirena IUD ® Non-hormonal methods www.fvleiden.org

  36. For Health Care Providers www.nattinfo.org NATT

  37. The Top 6 Questions I Get Asked 1. “What birth control options are there for women with h/o thrombosis or thrombophilia?” 2. “For the woman on warfarin, is it o.k. to take birth control pills?” 3. “What can the postmenopausal woman with h/o thrombosis or thrombophilia take for vaginal dryness?” 4. “What can be done about warfarin-associated fatigue?” 5. “What can be done about warfarin-associated hairloss?” 6. “What can be done about widely fluctuating INRs?”

  38. Summary • High / low likelihood of DVT/PE (Well’s criteria) • D-dimer if low likelihood of DVT/PE • Thrombolytics: occasionally • Outpatient Rx: yes, but assess feasability • Thrombophilia w/u • Length of warfarin (thrombophilias, ♂ > ♀; D-dimer; lifestyle) • Compression stockings (grade 2); stents; pumps • www.nattinfo.org • DVT Prophylaxis

More Related